Aatru Medical, LLC, a negative pressure wound therapy (NPWT) company, announced today that its peer-reviewed human clinical study has been published in PubMed Central. The full open-access text of the study can be found at Cureus: https://pmc.ncbi.nlm.nih.gov/articles/PMC12273889/

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804732819/en/

Aatru Medical NPSIMS

The publication, titled “Clinical Evaluation of a Novel, Chemically-Generated, Single-Use Negative Pressure Wound Therapy System for the Management of Closed Surgical Incisions,” was authored by scientific consultant Robin Martin, Ph.D., with input from the participating surgeons. The publication details a first-in-human clinical study of Aatru’s novel NPWT product called the NPSIMS™. to evaluate its safety and performance. The NPSIMS was successfully applied across multiple surgical incision types including spine, shoulder, and plastic surgery.

The clinical study showed that the novel, solid-state NPWT device, with vacuum provided by an internal oxygen-consuming chemical reaction, generated and maintained negative pressure and managed the exudate from closed incisions for a mean of 6.3 days. Participating clinicians familiar with other electromechanical, single-use NPWT devices welcomed the npSIMS devices. They were readily applied, convenient and easy to use. The products operated silently and demonstrated airtight sealing—useful features for clinical practice.

Covered by multiple US and foreign patents, the NPSIMS uses neither electrical or mechanical components, but instead utilizes a novel, micro solid-state chemical reaction to deliver negative pressure to the incision site. Unlike other NPWT products on the market, the commercially-launched NPSIMS was designed specifically for surgical incisions and offers an economical NPWT solution to hospitals and surgical centers.

Aatru Medical CEO, Timothy Wojciechowski stated, “This completed study and its publication are important milestones, and we are all really pleased with the outcome. Moreover, we are grateful for the work of the New Zealand medical teams and their coordinated efforts that made this study happen.”

About NPWT for closed surgical incisions:

Several post-operative wound complications are common following surgical procedures. NPWT is well recognized for the management of open wounds, and in the last several years has been applied to closed surgical incisions. Compared with standard postoperative dressings, NPWT significantly reduces the rate of wound infection and seroma. The global market opportunity for NPWT in the closed surgical incision market is approximately $14B annually with low single-digit market penetration to date.

About Aatru Medical:

Aatru is a privately-held medical device company that has commercially launched its FDA-cleared NPSIMS, a simple, disposable, single-use and low cost NPWT device designed for the surgical incision market. Its globally-patented design circumvents the need for an electromechanical pump, batteries, or canister. More information is available at: www.aatru.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250804732819/en/